IBB ETF Analysis: Biotechnology | NASDAQ
Health | NASDAQ, USA | Market Cap: 7.845m USD | 12M Return: 39.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 327M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The iShares Biotechnology ETF (IBB) primarily invests at least 80% of its assets in the component securities of its underlying index, providing exposure to publicly traded biotechnology companies. The remaining assets may be allocated to futures, options, swap contracts, and cash equivalents. As a non-diversified fund, it concentrates its holdings within the biotechnology sector, meaning its performance can be significantly influenced by a relatively narrow group of companies.
The biotechnology sector includes firms engaged in the research, development, and commercialization of therapies, vaccines, and diagnostic tools derived from biological processes, often characterized by lengthy development cycles and reliance on clinical trial outcomes and regulatory approvals.
- FDA approval decisions boost top holdings revenue outlook
- Drug pricing legislation pressures biotech profit margins
- Interest rate cuts lift high-growth biotech valuations
As of July 24, 2026, the stock is trading at USD 188.98 with a total of 1,290,226 shares traded. Over the past week, the price has changed by -0.28%, over one month by +6.11%, over three months by +10.19% and over the past year by +39.92%.
Current recommended Stop Loss: 184.20 (which is 2.5% or 1.3 ATR below the current price).
Biotechnology has no consensus analysts rating.